The outbreak of Delta Plus variant: The notorious and novel strain of SARS-CoV-2

Richi, Fahmida Tasnim; Alam, Safaet; Ahmed, Firoj; Al-Hossain, A.S.M. Monjur

doi:10.1016/j.cegh.2022.100974

Cited by 4 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 14 So far, several variants of concern (VOC) have been recognized. The Delta variant (B.1.617.2) and its close relative (Delta Plus, B.1.617.2.1) 15 were first reported in India and are associated with enhanced transmissibility and augmented virulence. 16 Studies have also reported that the UK variant (Alpha, B.1.1.7) has an augmented risk of transmission 17 and mortality.…”

Section: Introductionmentioning

confidence: 99%

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern

Kumar

Banurekha

Kumar

et al. 2022

Journal of Travel Medicine

View full text Add to dashboard Cite

Background Covaxin/BBV152 is one of the most widely used vaccines against SARS-CoV-2 infection and one of the few vaccines used extensively in low- and middle-income countries (LMIC). Methods We investigated the effect of Covaxin on the SARS-CoV-2 specific IgG and IgA and neutralizing antibody (NAb) levels at baseline (M0) and at months 1 (M1), 2 (M2), 3 (M3), 4 (M4), 6 (M6) and 12 (M12) following vaccination in health care workers. In addition, we also examined the NAb levels against variant lineages of B.1.617.2 (Delta, India), B.1.617.2.1 (Delta Plus, India), B.1.351 (Beta, SA), B.1.1.7 (Alpha, UK) and B.1.1.529 (Omicron). Results: Covaxin induces enhanced SARS-CoV-2 binding antibodies of IgG and IgA responses against both spike (S) and nucleocapsid (N) antigens at M1, M2, M3, M4, M6 and M12 in comparison to M0. Our data also reveal that NAb levels against the ancestral strain (Wuhan, Wild type) are elevated and sustained at M1, M2, M3, M4, M6 and M12 in comparison to M0 and against variant lineages of B.1.617.2 (Delta, India), B.1.617.2.1 (Delta Plus, India), B.1.351 (Beta, SA), B.1.1.7 (Alpha, UK) are elevated at M3, M6 and M12 in comparison to M0. However, NAb levels against B.1.1.529 (Omicron) was consistently below the limit of detection except at M12. Conclusion Thus, Covaxin induces an enhanced humoral immune response, with persistence till at least 12 months post-vaccination against most SARS-CoV-2 variants.

show abstract

Section: Introductionmentioning

confidence: 99%

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern

Kumar

Banurekha

Kumar

et al. 2022

Journal of Travel Medicine

View full text Add to dashboard Cite

show abstract

“…Delta Plus (B.1.617.2.1/(AY.1) is an Indian Delta variant with an additional K417 N mutation in Spike protein [ 25 ]. According to the Public Health England bulletin, the novel mutation was found in six genomes from India [ 26 ].…”

Section: Genomic Variations Of Sars-cov-2mentioning

confidence: 99%

Mutations of SARS-CoV-2 and their impact on disease diagnosis and severity

Alquraan

Alzoubi

Rababa'h

2023

Informatics in Medicine Unlocked

View full text Add to dashboard Cite

“…The dreadful spread of SARS-CoV-2 virus with its several arbitrarily mutated variants has been a severe global health concern due to the horrendous catastrophic effects on every sector of life across the world ( 1 , 2 ). Following the declaration of the COVID-19 outbreak as a pandemic on March 11, 2020 by WHO, an ample amount of confirmed cases of the infection and deaths are being reported throughout the world till now ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Experience and side effects of COVID-19 vaccine uptake among university students: a cross-sectional survey study

Islam,

Nahar,

Rahman

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

IntroductionMany people expressed concern over coronavirus vaccinations’ reliability and side effects. This research aimed to assess university students’ perceptions and experiences regarding the side effects of the COVID-19 vaccines in Bangladesh.MethodWe conducted an online cross-sectional survey to collect responses from university students vaccinated with any vaccines administered in Bangladesh between November 2021 to April 2022. Bangladeshi university students over the age of 18 and having an internet connection was included in the study. A binary logistic regression analysis along with Pearson’s Chi-square test were used to identify COVID-19 vaccine-related side effects predictors after receiving the first dose.ResultsA total of 1,176 participants responded voluntarily to the online study, and most were vaccinated. More than half of the participants received the Sinopharm vaccine (56.5%), while others received Covishield (8.9%), Moderna (7.3%), and Pfizer (5.8%) vaccine. Around 32% of the participants reported side effects after receiving the first dose of the vaccine, including pain and edema (78.4%), body temperature (20.3%), and headache (14.5%), while a few experienced allergy, anxiety, and uneasy feelings. About 17% of the participants reported experiencing side effects after the second dose of the vaccine, including pain and edema (7.5%), body temperature (8.8%), and headache (7.3%). Most side effects were significantly associated with the Moderna vaccine (p < 0.001). Female students and those previously infected with COVID-19 were significantly associated with the side effects after taking the first dose of the vaccine.ConclusionWe found that side effects are mild and did not pose a significant challenge to Bangladesh’s effort in managing and reducing the risk associated with the COVID-19 pandemic.

show abstract

The outbreak of Delta Plus variant: The notorious and novel strain of SARS-CoV-2

Cited by 4 publications

References 6 publications

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern

Mutations of SARS-CoV-2 and their impact on disease diagnosis and severity

Experience and side effects of COVID-19 vaccine uptake among university students: a cross-sectional survey study

Contact Info

Product

Resources

About